Business Description
AgomAb Therapeutics, founded in 2017 and based in Antwerp, Belgium, is working to create new treatments for chronic inflammatory and fibrotic diseases where patients currently have few effective options. Its two most advanced drugs ? Ontunisertib, taken by mouth for fibrostenosing Crohn's disease, and AGMB-447, an inhaled therapy for idiopathic pulmonary fibrosis ? are both in early-stage clinical trials and work by blocking a protein linked to scarring and tissue damage. The company is also developing AGMB-101, an antibody designed to reduce fibrosis and support tissue repair, which has shown promising results in early laboratory studies.
